News

Nov 5

NCC to initiate new research to develop nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), supported by PREMIA and Paradigm, to further accelerate precision medicine for patients.

The National Cancer Center (“NCC”), Precision Medicine Asia Co., Ltd. (“PREMIA”) and Paradigm Health Inc (“Paradigm”), announced the...

Sep 25

AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnosticfor AUGTYRO® (repotrectinib)

TOKYO and XIAMEN, September 25th, 2024 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia...

Jul 29

AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnosticfor Haiyitan® tablets (gumarontinib hydrate)

TOKYO and XIAMEN, July 25th, 2024 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co.,...

May 20

AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for TABRECTA™ (Capmatinib)

TOKYO and XIAMEN, May 20th, 2024 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd....

Mar 28, 2023

AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib...

TOKYO and XIAMEN, March 27, 2023 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd....

Dec 21, 2022

Premia and National Cancer Center Hospital East Announce the Initiation of the LC-SCRUM-AP Genomic..

Establishing a large-scale lung cancer genomic screening platform in the Asia-Pacific region and promoting precision medicine for lung...